Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/development-of-the-21-gene-assay-and-its-application-in-clinical-QWH3D9Eh8e
References (56)
-
S. Shak, G. Palmer, J. Baker (2007)
Re: Breast cancer gene microarrays pass muster.Journal of the National Cancer Institute, 99 7
-
(2005)
Oncotype Dx correlates more closely with prognosis than Adjuvant Online -
M. Buyse, S. Loi, L. Veer, G. Viale, M. Delorenzi, A. Glas, M. D'assignies, J. Bergh, R. Lidereau, P. Ellis, A. Harris, J. Bogaerts, P. Therasse, A. Floore, M. Amakrane, F. Piette, E. Rutgers, C. Sotiriou, F. Cardoso, M. Piccart (2006)
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.Journal of the National Cancer Institute, 98 17
-
L. Habel, S. Shak, M. Jacobs, A. Capra, C. Alexander, M. Pho, J. Baker, Michael Walker, D. Watson, J. Hackett, Noelle Blick, D. Greenberg, L. Fehrenbacher, B. Langholz, C. Quesenberry (2006)
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patientsBreast Cancer Research, 8
-
M. Vijver, Yudong He, L. Veer, H. Dai, A. Hart, D. Voskuil, G. Schreiber, J. Peterse, C. Roberts, M. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. Delahaye, Tony Velde, H. Bartelink, S. Rodenhuis, E. Rutgers, S. Friend, René Bernards (2002)
A gene-expression signature as a predictor of survival in breast cancer.The New England journal of medicine, 347 25
-
(2008)
Geneexpression profiles to predict distant metastasis -
T. Sørlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. Eisen, M. Rijn, S. Jeffrey, T. Thorsen, H. Quist, J. Matese, P. Brown, D. Botstein, P. Lønning, A. Børresen-Dale (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 98
-
(2005)
Association between the 21-gene recurrence score assay (RS) and risk of loco-regional failure in nodenegative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20 -
L. Gianni, M. Zambetti, K. Clark, J. Baker, M. Cronin, J. Wu, G. Mariani, Jaime Rodriguez, M. Carcangiu, D. Watson, P. Valagussa, R. Rouzier, W. Symmans, J. Ross, G. Hortobagyi, L. Pusztai, S. Shak (2004)
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 29
-
A. Jemal, R. Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu, Carol Smigal, M. Thun (2006)
Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 56
-
(2007)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100) -
M. Cronin, M. Pho, D. Dutta, J. Stephans, S. Shak, M. Kiefer, J. Esteban, J. Baker (2004)
Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.The American journal of pathology, 164 1
-
A. Kamal, C. Loprinzi, C. Reynolds, A. Dueck, X. Geiger, J. Ingle, R. Carlson, T. Hobday, E. Winer, E. Perez, M. Goetz (2007)
How well do standard prognostic criteria predict oncotype DX (ODX) scoresJournal of Clinical Oncology, 25
-
Xiao-Jun Ma, S. Hilsenbeck, Wilson Wang, L. Ding, D. Sgroi, R. Bender, C. Osborne, D. Allred, M. Erlander (2006)
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 28
-
Howard Chang, D. Nuyten, Julie Sneddon, T. Hastie, R. Tibshirani, T. Sørlie, H. Dai, Yudong He, L. Veer, H. Bartelink, M. Rijn, P. Brown, M. Vijver (2005)
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.Proceedings of the National Academy of Sciences of the United States of America, 102 10
-
S. Paik, S. Shak, G. Tang, Chungyeul Kim, J. Baker, M. Cronin, F. Baehner, M. Walker, D. Watson, T. Park, W. Hiller, E. Fisher, D. Wickerham, J. Bryant, N. Wolmark, Genomic Health, Redwood City, S. Francisco (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.The New England journal of medicine, 351 27
-
C. Fan, D. Oh, L. Wessels, B. Weigelt, D. Nuyten, A. Nobel, L. Veer, C. Perou (2006)
Concordance among gene-expression-based predictors for breast cancer.The New England journal of medicine, 355 6
-
D. Ransohoff (2004)
Rules of evidence for cancer molecular-marker discovery and validationNature Reviews Cancer, 4
-
B. Fisher, J. Dignam, B. Emir, J. Bryant, A. DeCillis, N. Wolmark, D. Wickerham, N. Dimitrov, N. Abramson, J. Atkins, H. Shibata, L. Deschênes, R. Margolese (1997)
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.Journal of the National Cancer Institute, 89 22
-
C. Perou, S. Jeffrey, M. Rijn, Christian Rees, M. Eisen, D. Ross, Alexander Pergamenschikov, Cheryl Williams, Shirley Zhu, Jeffrey Lee, D. Lashkari, D. Shalon, P. Brown, D. Botstein (1999)
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.Proceedings of the National Academy of Sciences of the United States of America, 96 16
-
B. Fisher, J. Costantino, C. Redmond, R. Poisson, D. Bowman, J. Couture, N. Dimitrov, N. Wolmark, D. Wickerham, Edwin Fisher, R. Margolese, A. Robidoux, H. Shibata, J. Terz, A. Paterson, M. Feldman, W. Farrar, James Evans, H. Lickley, Mary Ketner (1989)
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.The New England journal of medicine, 320 8
-
S. Loi, M. Piccart, C. Sotiriou (2007)
The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response.Critical reviews in oncology/hematology, 61 3
-
I. Olivotto, C. Bajdik, P. Ravdin, C. Speers, A. Coldman, B. Norris, G. Davis, S. Chia, K. Gelmon (2005)
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 12
-
(2007)
: An economic analysis based on prognostic and predictive validation studies -
Oratz R, Paul D, Cohn A (2006)
Impact of Oncotype DX on decision making in breast cancer clinical practice -
S. Hanash (2004)
Integrated global profiling of cancerNature Reviews Cancer, 4
-
L. Carey, E. Dees, L. Sawyer, Lisa Gatti, D. Moore, F. Collichio, D. Ollila, Carolyn Sartor, M. Graham, C. Perou (2007)
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 13
-
A. Harris, A. Harris (2005)
REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 93
-
(2006)
Relationship between proliferation genes and expression of hormone and growth factor receptors: Quantitative RT-PCR in 10,618 breast cancers -
J. Sparano (2006)
TAILORx: trial assigning individualized options for treatment (Rx).Clinical breast cancer, 7 4
-
Richard Simon (2003)
Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray dataBritish Journal of Cancer, 89
-
M. Goetz, V. Suman, J. Ingle, Andrea Nibbe, D. Visscher, C. Reynolds, W. Lingle, M. Erlander, Xiao-Jun Ma, D. Sgroi, E. Perez, F. Couch (2006)
A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant TamoxifenClinical Cancer Research, 12
-
Goldstein LJ, Gray, R, Badve, S
Prognostic utility of the 21-gene assay in hormone receptor positive operable breast cancer compared with Adjuvant!, an integrator of clinicopathologic and treatment information -
B. Fisher, J. Jeong, J. Dignam, S. Anderson, E. Mamounas, D. Wickerham, N. Wolmark (2001)
Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.Journal of the National Cancer Institute. Monographs, 30
-
J. Foekens, D. Atkins, Yi Zhang, F. Sweep, N. Harbeck, A. Paradiso, T. Čufer, A. Sieuwerts, D. Talantov, P. Span, V. Tjan-Heijnen, A. Zito, K. Specht, H. Hoefler, R. Golouh, F. Schittulli, M. Schmitt, L. Beex, J. Klijn, Yixin Wang (2006)
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 11
-
Kim C, Tang G, Baehner FL (2006)
A comparison of estrogen receptor (ER) measurement by three methods in node negative, estrogen receptor (ER) positive breast cancer: Ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PC -
L. Goldstein, R. Gray, S. Badve, B. Childs, C. Yoshizawa, Steve Rowley, S. Shak, F. Baehner, P. Ravdin, N. Davidson, G. Sledge, E. Perez, L. Shulman, S. Martino, J. Sparano (2008)
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 25
-
R. Carlson, Elizabeth Brown, H. Burstein, W. Gradishar, C. Hudis, C. Loprinzi, E. Mamounas, E. Perez, K. Pritchard, P. Ravdin, A. Recht, G. Somlo, R. Theriault, E. Winer, A. Wolff (2006)
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.Journal of the National Comprehensive Cancer Network : JNCCN, 4 Suppl 1
-
K. Dobbin, R. Simon (2007)
Sample size planning for developing classifiers using high-dimensional DNA microarray data.Biostatistics, 8 1
-
(2006)
The impact on the recurrence score due to patient variation in the quantitative expression of individual genes or gene groups -
R. Simon, M. Radmacher, K. Dobbin, L. McShane (2003)
Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.Journal of the National Cancer Institute, 95 1
-
Wang Y, Klijn JG, Zhang Y (2005)
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancerLancet, 365
-
B. Fisher, Jong-Hyeon Jeong, J. Bryant, S. Anderson, J. Dignam, E. Fisher, N. Wolmark (2004)
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trialsThe Lancet, 364
-
P. Isaacson, M. Du (2004)
MALT lymphoma: from morphology to moleculesNature Reviews Cancer, 4
-
B. Hillner (2008)
Impact of a 21-Gene RT-PCR Assay on Treatment Decisions in Early-Stage Breast CancerBreast Diseases: A Year Book Quarterly, 18
-
Medicare, Medicaid and CLIA programs (1992)
Regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA)-HCFA-Final rule with comment periodFed Regist, 57
-
S. Paik, G. Tang, S. Shak, Chungyeul Kim, J. Baker, W. Kim, M. Cronin, F. Baehner, D. Watson, J. Bryant, J. Costantino, C. Geyer, D. Wickerham, N. Wolmark (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 23
-
S. Lo, J. Norton, P. Mumby, J. Smerage, J. Kash, H. Chew, D. Hayes, A. Epstein, K. Albain (2007)
Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selectionJournal of Clinical Oncology, 25
-
K. Dobbin, R. Simon (2005)
Sample size determination in microarray experiments for class comparison and prognostic classification.Biostatistics, 6 1
-
R. Rouzier, C. Perou, W. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson, K. Hess, J. Stec, J. Stec, M. Ayers, P. Wagner, P. Morandi, Chang Fan, Islam Rabiul, J. Ross, G. Hortobagyi, L. Pusztai (2005)
Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 11
-
S. Paik, S. Shak, G. Tang, Chungyeul Kim, J. Baker, M. Cronin, D. Watson, J. Bryant, J. Costantino, N. Wolmark (2005)
Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancerJournal of Clinical Oncology, 23
-
Lyman GH, Cosler LE, Kuderer NM (2007)
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studiesCancer, 109
-
M. Cronin, C. Sangli, Mei-lan Liu, M. Pho, D. Dutta, Anhthu Nguyen, Jennie Jeong, J. Wu, K. Langone, D. Watson (2007)
Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.Clinical chemistry, 53 6
-
Howard Chang, Julie Sneddon, Ash Alizadeh, R. Sood, R. West, K. Montgomery, J. Chi, M. Rijn, D. Botstein, P. Brown (2004)
Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and WoundsPLoS Biology, 2
-
K. Albain, W. Barlow, S. Shak, G. Hortobagyi, R. Livingston, I. Yeh, P. Ravdin, R. Bugarini, F. Baehner, N. Davidson, G. Sledge, E. Winer, C. Hudis, J. Ingle, E. Perez, K. Pritchard, L. Shepherd, J. Gralow, C. Yoshizawa, D. Allred, C. Osborne, D. Hayes (2009)
Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100).Cancer Research, 69
-
Daniel Hayes, D. Hayes, R. Bast, C. Desch, H. Fritsche, N. Kemeny, J. Jessup, G. Locker, J. Macdonald, R. Mennel, Larry Norton, P. Ravdin, S. Taube, R. Winn (1996)
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.Journal of the National Cancer Institute, 88 20
- Publisher
- Wolters Kluwer Health
- Copyright
- (C) 2008 American Society of Clinical Oncology
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- DOI
- 10.1200/JCO.2007.15.1068
- Publisher site
- See Article on Publisher Site
Abstract
ABSTRACT: Several multigene markers that predict relapse more accurately than classical clinicopathologic features have been developed. The 21-gene assay was developed specifically for patients with estrogen receptor (ER)-positive breast cancer, and has been shown to predict distant recurrence more accurately that classical clinicopathologic features in patients with ER-positive breast cancer and negative axillary nodes treated with adjuvant tamoxifen; validation studies in this population led to its approval as a diagnostic test. In a similar population, it also may be used to assess the benefit of adding chemotherapy to hormonal therapy. Other validation studies indicate that it also predicts the risk of distant and local recurrence in other populations with ER-positive disease, including node-negative patients receiving no adjuvant therapy and patients with positive axillary nodes treated with doxorubicin-containing chemotherapy. The Trial Assigning Individualized Options for Treatment (TAILORx) is multicenter trial that integrates the 21-gene assay into the clinical decision-making process and is designed to refine the utility of the assay in clinical practice and to provide a resource for evaluating additional molecular markers as they are developed in the future.
Journal
Journal of Clinical Oncology – Wolters Kluwer Health
Published: Feb 10, 2008